As noted, I’m not so interested in the worth -– or market potential –- of this new drug from Amylin Pharmaceuticals as I am in the actual value to patients. I was initially excited and intrigued by this first new offering to help Type 1 diabetics since insulin in the 1920s. Yet after querying several doctors and a number of patients who chose to stay on Symlin after participating in a study, I must say…
Read more »
The FDA approval of Symlin is making big headlines, and last week I had a bunch of relatives contact me, as they tend to do, when something new and “hot” appears on the diabetes scene. The drug is targeted toward Type 1 diabetics who don’t achieve good BG control despite insulin treatments. It was apparently 18 years in the making, and is the first new drug to be marketed to Type 1 diabetics since insulin…
Read more »
Powder form? Are they kidding me? Am I the only one mystified by the concept of new inhalable insulin? How the heck does dosing work?
Exubera. Sounds fun, ay? Apparently one inhales it before meals using a device which I’m assuming looks like an asthma inhaler. So how much is a unit, I wonder? And how can the inhaler set unit dosages precise enough for insulin-sensitive folks like me, who respond to half-units of the…
Read more »